Clinical Investigation of the Safety of the MediSieve Magnetic Haemofiltration System in Healthy Volunteers

This is a single-centre, non-randomised, prospective study to assess the safety of the MediSieve blood filtration system in healthy volunteers

Study Overview

• Status: Completed
• Conditions: Haemofiltration
• Intervention / Treatment: Device: MediSieve Magnetic Haemofiltration System

Detailed Description

The MediSieve Magnetic Haemofiltration System (MMHS) is a system to filter selected moieties from blood in an extracorporeal circuit by magnetic means. Initially, it is developed for the treatment of severe malaria to capture malaria-infected erythrocytes (who are weakly magnetic) to reduce the parasitaemia. However, the use of MMHS can be extended, with the use of antibodies coupled to magnetic beads, to other diseases, such as sepsis.

The MMHS has to be used first in healthy volunteers to determine its clinical safety.

To this end, 6 healthy male and female volunteers (ratio 1:1) will undergo blood filtration using the MediSieve Magnetic Haemofiltration System (without magnetic beads) for five consecutive hours. Vital signs will be continuously monitored and blood samples will be obtained serially to determine laboratory safety and immunological parameters. Furthermore, volunteers will have two follow up visits at 24 hours and 7 days post filtration.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Gelderland
    • Nijmegen, Gelderland, Netherlands, 6525GA
      • Radboud University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female, ≥18 and ≤50 years of age
• Able to comprehend and sign the Information letter and Informed Consent (IC) prior to enrolment in the study.

Exclusion Criteria:

• BMI <18.5 or >30 kg/m2
• Chronic medication use (except contraception)
• Pregnant or lactating females
• Known anaphylaxis or hypersensitivity to any (non-)investigational products or their excipients
• History or signs of severe atopic syndrome (asthma, rhinitis with medication and/or eczema)
• History or signs of haematological disease
• History or signs of thromboembolic disorders
• History of (intracranial) aneurysmal or haemorrhagic diseases
• History of any disease associated with immune deficiency
• History of cancer in the last 5 years (excluding localised skin cancer or CIS)
• History of heparin-induced thrombocytopenia (HIT)
• History of peptic / gastric ulcer disease
• Family history of haemorrhagic or thromboembolic disorders (<50 years of age)
• Thrombocytopenia (<150*109/ml) or anaemia (males: haemoglobin < 8.0 mmol/L, females: haemoglobin < 7.4 mmol/L)

• History, signs or symptoms of cardiovascular disease, in particular:

  • Prone to vagal collapse
  • History of atrial or ventricular arrhythmia
  • Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrio-ventricular block or a complete left bundle branch block
  • Hypertension (defined as RR systolic > 160 or RR diastolic > 90 mmHg)
  • Hypotension (defined as RR systolic < 100 or RR diastolic < 50 mmHg)
• Renal impairment (defined as plasma creatinine >120 μmol/L)
• Liver enzyme abnormalities (above 2x the upper limit of normal)
• Signs of infection (CRP > 20 mg/L, White Blood Count > 12x109/L or < 4x109/L)
• Clinically significant acute illness, including infections or trauma, within 1 month of the experiment day
• Participation in an experimental intervention or drug trial or donation of blood within 3 months prior to the experiment day
• Recent hospital admission or surgery with general anaesthesia within 3 months prior to experiment day
• Use of recreational drugs within 2 weeks of the experiment day
• Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and/or take part in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Treatment; All volunteers will receive the same treatment	Device: MediSieve Magnetic Haemofiltration System; The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream. Healthy volunteers will undergo filtration for 5 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety (Adverse events)	Incidence of (serious) adverse events and device deficiencies during haemofiltration until 7 days post-filtration	Continuously starting from 2 hours prior of the start of haemofiltration until 7 days post-filtration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety (Blood pressure)	Systolic, diastolic and mean arterial pressure will be measured continuously using a radial artery catheter.	From 2 hours prior until 7 hours after start of haemofiltration.
Safety (Heart rate)	Heart rate will be recorded continuously using a 3-lead ECG.	Continuously from 2 hours prior until 7 hours after start of haemofiltration.
Safety (Temperature)	Body temperature will be assessed by using tympanic temperature measurements.	Every 30 minutes from 2 hours prior until 7 hours after start of haemofiltration.
Safety (Symptoms)	Clinical symptoms will be scored on a Likert scale (ranging from 0 to 5) in a composite endpoint consisting of headache, nausea, shivering, muscle soreness and lower back pain. Higher numbers indicate more severe symptoms.	Every 30 minutes from 2 hours prior until 7 hours after start of haemofiltration.
Safety (Immunology)	The following plasma cytokines will be measured (pg/mL): Tumour necrosis factor (TNF), Interleukin (IL)-6, IL-8, IL-10, IL-1 receptor antagonist (IL-1RA), Monocyte Chemoattractant Protein (MCP)-1, Macrophage Inflammatory Protein (MIP)-1α, MIP-1β, Interferon-γ induced Protein (IP)-10, and Granulocyte Colony-Stimulating Factor (G-CSF)	Samples will be obtained from 1 hour prior until 7 days after start of haemofiltration.
Safety (Metal analysis)	Plasma concentration levels of chromium and manganese will be measured in nmol/L.	Samples will be obtained from start of haemofiltration, and after 1 hour, 5 hours, 24 hours and 7 days.
Safety (Cell counts)	Leukocytes (including differentation), erythrocytes and thrombocytes will be measured in *10^9/L.	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.
Safety (Haemoglobin and elektrolytes)	Haemoglobin, sodium, potassium, calcium, phosphate, magnesium, and urea will be measured in mmol/L	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.
Safety (Haematocrit)	Haematocrit will be measured in L/L.	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.
Safety (Coagulation)	Prothrombin time (PT), activated clotting time (ACT) and activated partial thromboplastin time (APTT) will be measured in seconds.	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.
Safety (INR)	International Normalized Ratio (INR) will be measured to assess coagulation.	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.
Safety (Fibrinogen + albumin)	Fibrinogen and albumin will be measured in grams/L.	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.
Safety (Kidney function)	Kidney function will be measured in mL/min/1.73m^2.	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.
Safety (Markers associated with cellular damage)	Cellular damage will be assessed by measuring Alanine Aminotransferase (ALAT), Aspartate Aminotransferase (ASAT), Lactate Dehydrogenase (LDH), Creatine kinase (CK), Alkaline phosphatase (AP)	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.
Safety (C-reactive protein)	C-reactive protein (CRP) will be measured in mg/L.	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.
Safety (Creatinine and iron status)	Creatinine, iron and total iron binding capacity (TIBC) will be measured in umol/L.	Samples will be obtained from 2 hours prior until 7 days after start of haemofiltration.

Collaborators and Investigators

• Sponsor: MediSieve Limited
• Collaborators: Radboud University Medical Center

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 13, 2022
• Primary Completion (ACTUAL): November 17, 2022
• Study Completion (ACTUAL): November 30, 2022

Study Registration Dates

• First Submitted: January 10, 2023
• First Submitted That Met QC Criteria: February 1, 2023
• First Posted (ACTUAL): February 6, 2023

Study Record Updates

• Last Update Posted (ACTUAL): February 6, 2023
• Last Update Submitted That Met QC Criteria: February 1, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: MediSieve FMS study

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No